Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
80 participants
INTERVENTIONAL
2021-10-20
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The fascia iliaca compartment (FIC) block has become a familiar technique to emergency physicians as a pain control treatment for hip fractures. The pericapsular nerve group (PENG) block has recently been proposed as a novel method to treat pain due to hip, acetabular and pelvic fracture by targeting the terminal sensory articular nerve branches of the femoral nerve (FN), obturator nerve (ON), and accessory obturator nerve (AON). At this time there has been no study comparing the efficacy of the two nerve blocks, PENG and FIC.
This aim of this study is to compare the efficacy of the PENG block (20mL of Bupivacaine 0.50%) to that of the FIC block (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED. Our hypothesis is that PENG will demonstrate analgesia that is non-inferior to FIC. Subjective pain scores on a scale of 0 to 10 will be assessed before and after the block. All subjects will receive 4mg of morphine after consent and prior to the block.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PENG vs. FIC Blocks in Hip Fractures in the ED
NCT06336460
PENG vs FICB for Hip Fracture in ED Patients
NCT05505604
Comparison of PENG Block and FICB in Hip Fracture Patients
NCT04677348
Efficacy of Pericapsular Nerve Group Block
NCT05154318
PENG Block vs Fascia Iliaca Block for Emergency Department Analgesia in Hip Fractures
NCT05370586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The fascia iliaca compartment (FIC) block has become a familiar technique to emergency physicians as a pain control treatment for hip fractures. The pericapsular nerve group (PENG) block has recently been proposed as a novel method to treat pain due to hip, acetabular and pelvic fracture by targeting the terminal sensory articular nerve branches of the femoral nerve (FN), obturator nerve (ON), and accessory obturator nerve (AON). At this time there has been no study comparing the efficacy of the two nerve blocks, PENG and FIC.
This aim of this study is to compare the efficacy of the PENG block (20mL of Bupivacaine 0.50%) to that of the FIC block (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED. Our hypothesis is that PENG will demonstrate analgesia that is non-inferior to FIC. Subjective pain scores on a scale of 0 to 10 will be assessed before and after the block. All subjects will receive 4mg of morphine after consent and prior to the block.
A secondary aim is to show that the PENG block is preferable to the FIC block because it does not target motor nerves, thus preserving motor function allowing for an accurate neurological exam and hopefully providing for earlier ambulation. Also, we aim to determine if PENG block results in an significant reduction in amount of systemic pain medication needed for the patient.
This is a single-centered, prospective, randomized, blinded study involving patients who present to the ED with an isolated hip fracture. Patients who meet inclusion criteria will be consented for the study and then randomized to receive either a FIC block or a PENG block. Patients who are potentially to be enrolled in the study will receive standardized systemic analgesia while awaiting x-rays. If needed, patients will be administered morphine for breakthrough pain after the nerve blocks are placed. The exception to this standardization will be patients with a morphine allergy.
The research associate will screen for patients and confirm with the attending physician that the subject is eligible for enrollment and is able to give consent. The patient consented by a member of the research team, who will assess the patient's pain score on a scale of 0 to 10 prior to the block. The patient will then be randomized to receive either the FIC block or the PENG block to be performed by a member of the ultrasound faculty. The research associate will be blinded to the type of block being performed by the ultrasound faculty member. The research associate will then reassess the patient's pain score on the 0-10 scale at the 30 minute and 60-minute mark. They will also assess for any adverse events after the block is performed. The research associate will note the motor function in the quadriceps muscle 30 min and 60 min after the nerve block is placed. Any rescue medication given after the nerve block is placed in the ED will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fascia Iliaca Compartment
Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED
Nerve Block using FIC Proceedure
Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
PENG Block
Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
Nerve Block using PENG Proceedure
Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nerve Block using FIC Proceedure
Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
Nerve Block using PENG Proceedure
Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Isolated hip fracture, intertrocanteric or more proximal
* Pain score 5 or greater on a scale of 0 to 10 just prior to nerve block placement
Exclusion Criteria
* People who are unable to communicate their level of pain\\
* Pregnant patients
* Pediatric Patients (less than 18 years of age)
* Intoxicated Patients
* Abnormal Vital Signs (HR\>120bpm, MAP \<65, Pulse Ox \<95%)
* Patients on long term systemic opioid analgesia
* Allergy to amide local anesthetics
18 Years
110 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Antonios Likourezos
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonios Likourezos
Research Administration Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lawrence Haines, MD
Role: PRINCIPAL_INVESTIGATOR
Maimonides Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maimonides Medical Center
Brooklyn, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-02-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.